Our top pick for
US stocks

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Mediland Pharm is a consumer discretionary business based in Australia. Mediland Pharm shares (MPH) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Mediland Pharm has a trailing 12-month revenue of around $1.2 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Long-term investing
Our top pick for
Low-cost broker
52-week range | $0.045 - $0.075 |
---|---|
50-day moving average | $0.0701 |
200-day moving average | $0.0638 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.058
6 months (2021-12-29) | -1.69% |
---|
1 year (2021-06-29) | 7.41% |
---|---|
2 years (2020-06-29) | -42.00% |
3 years (2019-06-28) | -82.94% |
Valuing Mediland Pharm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Mediland Pharm 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Mediland Pharm 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $654,369 (£371,641).
The EBITDA is a measure of a Mediland Pharm 's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $1.2 million |
---|---|
Gross profit TTM | $55,675 |
Return on assets TTM | -15.02% |
Return on equity TTM | -106.43% |
Profit margin | 0% |
Book value | 0.01 |
Market capitalisation | $18.8 million |
TTM: trailing 12 months
We're not expecting Mediland Pharm to pay a dividend over the next 12 months.
Over the last 12 months, Mediland Pharm 's shares have ranged in value from as little as $0.045 up to $0.075. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Mediland Pharm 's is 0.5447. This would suggest that Mediland Pharm 's shares are less volatile than average (for this exchange).
Innlanz Limited, together with subsidiaries, engages in the retail sale of health and wellness products and supplements. The company operates through three segments: Retailer servicing the Chinese inbound tourism sector in Australia and New Zealand, Online sales through E-commerce Platform, and Hotel operations. It also operates retail stores. The company was formerly known as Mediland Pharm Limited. Innlanz Limited was founded in 2002 and is based in Parramatta, Australia.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.